{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.96","upperLimit":"56.59","value":"49.8"},{"groupId":"OG001","lowerLimit":"52.25","upperLimit":"61.80","value":"57.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"description":"Clinical benefit is defined as the achievement of CR, PR, or stable disease according to RECIST v1.1 that lasts for at least 6 months. CR is defined as the disappearance of all TLs and SA reduction to \\<10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference smallest SD since treatment started.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Clinical Benefit Rate analysis included all participants with unconfirmed PR/CR or SD of at least 6 months duration","reportingStatus":"POSTED","timeFrame":"From Day 1 to PD, assessed up to primary completion date (approximately 26 months)","title":"Percentage of Participants With Clinical Benefit Assessed Using RECIST v1.1 in Response-evaluable Population","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}